The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 14, 2025

Filed:

Dec. 24, 2019
Applicant:

Hinova Pharmaceuticals Inc., Sichuan, CN;

Inventors:

Wu Du, Sichuan, CN;

Yu Li, Sichuan, CN;

Kun Wen, Sichuan, CN;

Xinghai Li, Sichuan, CN;

Yuanwei Chen, Sichuan, CN;

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/506 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07D 403/12 (2006.01);
U.S. Cl.
CPC ...
A61K 31/506 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C07D 403/12 (2013.01); C07B 2200/05 (2013.01);
Abstract

A deuterated compound as represented by formula (I) or an optical isomer, a tautomer, a pharmaceutically acceptable salt, a prodrug, a hydrate, or a solvate thereof are presented. Compared with a compound before deuteration, the deuterated compound shows better pharmacokinetics, higher maximum plasma drug concentration, higher exposure, and longer half-life, and has more excellent metabolic performance. The deuterated compound can effectively inhibit FAK activity, and has good application prospect in preparation of FAK inhibitors and/or drugs for treating cancer. In addition, the use of the deuterated compound in combination with an anti-cancer drug (such as a PD-1 inhibitor) can achieve a synergistic effect, thereby significantly improving the tumor suppression effect, and providing a better choice for clinical cancer treatment.


Find Patent Forward Citations

Loading…